Thursday, July 9, 2026

pharma · Hypercholesterolemia · Hyperlipidemia · ESPR

Esperion Therapeutics

Espervita Therapeutics is a pharma organization headquartered in ann arbor, USA. It trades on NYSE under ticker ESPR. Primary therapeutic focus areas include Hypercholesterolemia, Hyperlipidemia, Cardiovascular Diseases,

Ann Arbor, US HQ
5 Employees
Public company Type
ESPR · NYSE Ticker
Company details
Status
Public
HQ
Ann Arbor, US
Employees
5
Programs
15
Drugs
9
Patents
55
Clinical program

Bempedoic acid + Ezetimibe FDC Oral Tablet

Phase 2 · small molecule · Diabetes

Bempedoic acid + Ezetimibe FDC Oral Tablet for Diabetes is a Phase 2 program (small_molecule) at Esperion Therapeutics with 1 ClinicalTrials.gov record(s).

← All Esperion Therapeutics projects Phase 2 small molecule completed

Internal code 1002FDC-058

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Esperion Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Diabetes
Status
completed
Trials
1